Cambridge Healthtech Institute’s 6th Annual

Managing Outsourced Clinical Trials

Building Successful Partnerships with Effective Oversight, Risk Mitigation & Resource Management

February 20-21, 2020


As more clinical trial activities are outsourced to CROs and other third-party vendors, and as those CROs and vendors grow in their capabilities, it is more important than ever for sponsors and vendors to develop strong partnerships and establish themselves as partners of choice. CHI’s 6th Annual Managing Outsourced Clinical Trials conference features case studies and lessons learned from sponsors and CROs on managing relationships, vendor quality and performance in light of the new ICH E6 R2 changes, and how to build beneficial partnerships that effectively manage resources.

Arrive early and attend Part 1 (Wed - Thurs): Mastering an Outsourcing Strategy

Final Agenda

Thursday, February 20

11:30 am Registration Open

12:30 pm BRIDGING LUNCHEON PRESENTATION: Data Certainty from Source to Submission: Addressing Disparate Data Challenges with eSource

Andrus_JonathanJonathan Andrus, Chief Business Officer, Clinical Ink

Poor clinical trial data collection can delay decisions that help study stakeholders confidently move products to market. This presentation covers:


  • The benefits of direct data capture using eSource technologies
  • How eSource solutions improve data capture, access and interoperability
  • How eSource helps companies enable true risk-based and remote monitoring approaches
  • How ePRO and eCOA improve site and patient engagement
  • Why investing in a disruptive solution both decreases study cost and creates a new revenue stream

1:00 Coffee and Dessert Break in the Exhibit HallBioTelResearch

 

2:00 Afternoon Plenary Keynotes

3:10 Booth Crawl & Refreshment Break in the Exhibit Hall. Last Chance for Exhibit Viewing

BEST PRACTICES IN MANAGING RELATIONSHIPS

4:10 Chairperson’s Remarks

Rosalie Filling, Vice President, Clinical Operations, Research and Development, Endo Pharmaceuticals

4:15 The Value of Supplier Relationship Management: CROs vs. Technology Outsourcing

Emmons_KristaKrista Emmons, Associate Director, Portfolio Relationship Management, R&D Procurement, Astellas Pharma

This talk will discuss how Supplier Relationship Management can bring value to the business beyond savings and describe tailoring your approach to a range of suppliers, from CROs to technology solutions. We’ll cover lessons learned from sitting on both sides of the table – from both the sponsor and vendor perspective.

4:45 Managing Offshore Outsourcing of Clinical Trial Research

Bae_MinjiMinji Bae, Associate Director, Vendor Management, AbbVie

This presentation will describe how to be operationally ready when onboarding offshore providers in BRIC countries, including the outcomes and models utilized to ensure successful sustainability of the offshore engagements, as well as lessons learned from challenges and opportunities.

5:15 Presentation to be AnnouncedICON-Corp

 

5:45 INTERACTIVE PANEL: Supplier Relationship Management: Various Journeys in Supplier Relationship Management “SRM” & Vendor Management “VM”

Santacruz_JohnModerator: John Santacruz, Director, Portfolio Relationship Management, R&D Procurement, Astellas Pharma


Hovda_AmandaPanelists: Amanda Hovda, MBA, Associate Director, Business Strategy & Operations, Analytics and Data Sciences, Biogen


Voolich_GretchenGretchen Voolich, Associate Director, R&D External Operations, R&D Quality, Operations & Performance, Biogen


Wool_LizLiz Wool, President, Wool Consulting Group

Hear stories from the panel on various journeys in Supplier Relationship Management “SRM” & Vendor Management “VM”, including:


  • Various Models & Value Propositions
  • Launches & Sustainability
  • Lessons Learned & Best Practices in Value Creation & Capture

6:15 Networking Reception (Sponsorship Opportunity Available)

7:15 Close of Day

Friday, February 21

7:15 am Registration Open

7:45 Breakfast Presentation to be Announced

8:15 Session Break

VENDOR OVERSIGHT: METRICS, KPIs AND ICH E6 R2

8:20 Chairperson’s Remarks

8:25 Defining Metrics for Quality Vendor Oversight

Dorricott_KeithKeith Dorricott, Ambassador, Metrics Champion Consortium; Director, DMPI Ltd.

ICH E6 R2 highlights the importance of CRO and third-party vendor oversight. Measuring whether timelines are met and financial aspects is relatively easy, but measuring quality can be much more challenging. While developing a set of metrics for quality oversight of CROs and vendors, an industry consortium of sponsors and vendors have uncovered many learnings from the bringing together of experiences across the industry. This presentation aims to share some of the key learnings and provide an overview of the metrics developed.

8:55 CO-PRESENTATION: Right-Sizing an R&D Approach for Optimizing Vendor Oversight

Hovda_AmandaAmanda Hovda, MBA, Associate Director, Business Strategy & Operations, Analytics and Data Sciences, Biogen


Voolich_GretchenGretchen Voolich, Associate Director, R&D External Operations, R&D Quality, Operations & Performance, Biogen


R&D outsourcing strategies are a highly discussed, highly debated, current topic within our industry with organizations utilizing slightly different approaches. At Biogen, oversight of R&D vendors is a shared responsibility using a risk-based model for the routine and watchful management of how we engage with our critical external relationships. The purpose of this presentation is to share Biogen’s approach of how everyone within the GxP and non-GxP environments owns oversight to drive internal accountability and vendor performance.

9:25 Sponsor Oversight in a Fully Outsourced Model: Small Biopharma Perspective

McLaughlin_MichaelMichael McLaughlin, Associate Director, Clinical Operations, Dermavant Sciences, Inc.


PAREXEL9:55 Presentation to be Announced

10:25 Networking Coffee Break

IMPLICATIONS OF RESOURCE AVAILABILITY ON OUTSOURCING AND OPERATIONS

10:55 Chairperson’s Remarks

Audrey Rossow, Senior Director, Clinical Operations, Pulmatrix, Inc.

11:00 How Many Internal ClinOps Resources Should You Have For Study Startup?

Rossow_Audrey-001Audrey Rossow, Senior Director, Clinical Operations, Pulmatrix, Inc.

In most biotech companies, budgets are small and timelines are as tight as possible in order to get the data needed to support the next round of funding and the next step in your clinical development program. The best way to achieve the next step is proper planning ahead. This presentation will focus on proper resourcing of a sponsor’s internal Clinical Operations team to support a clinical trial during startup.

11:30 Sponsored Presentation (Opportunity Available)

12:00 pm Transition to Shared Sessions

IMPLICATIONS OF RESOURCE AVAILABILITY ON OUTSOURCING AND OPERATIONS (CONT.)

12:05 Transparency is Key to Successfully Enable Vendor Partnerships Align on Resource Demands

Eric Lawrence, MBA, MS, Associate Director, Clinical Biomarker Specialty Lab Alliance Lead, Bristol-Myers Squibb

Successful execution of a study supported by third party vendors begins with transparency of expectations.  When a strategic partner is selected by multiple study teams with no visibility for competing resources from an enterprise perspective, the opportunity for risks to the portfolio become evident.  Strategies to mitigate pitfalls with external providers to ensure successful execution and success for the partnership will be reviewed.

12:35 INTERACTIVE PANEL: How Varying Resource Availability Affects Outsourcing, Operations and Pressures in Large vs. Small Pharma

Bradley_CharlesModerator: Chuck Bradley, Vice President, Clinical Development, FibroGen, Inc.


OBoyle_ErinPanelists: Erin O’Boyle, Senior Director, Clinical Operations, Rezolute, Inc.


Bonner_Wes-001Wes Bonner, VP, Strategic Development, Meridian Clinical Research


Theison,_PietPiet Theisohn, Director, Head, Resource Management in Clinical Operations, R&D-ClinOps - Business Excellence & Innovation, Bayer AG Pharma Division

This panel will highlight key differences in how large and small pharma companies address clinical operations due to varying amounts of resources. Panelists will address questions, such as:

  • How does resource availability affect the outsourcing strategy?
  • How do small and large pharma companies work with CROs on timelines, deliverables and meeting targets?
  • How do different-sized companies prioritize milestones, and what types of risk mitigation are put into place?

1:05 Transition to Lunch

1:10 SCOPE Send Off Luncheon Presentation (Sponsorship Opportunity Available)

1:40 Closing Remarks

1:45 SCOPE Summit 2020 Adjourns

PLENARY KEYNOTES

Tuesday Evening, Wednesday Morning, Wednesday Afternoon Plenary Keynotes Featuring:

SCOPE’s 2020 Participant Engagement Award, in Memory of Jerry Matczak
Patient Perspectives as an Input to Feasibility and Clinical Trial Design
Digital Trends that Are Changing Clinical Research
Health Literacy Throughout Drug Development – Why It Matters to Pharma and to Patients
Implementing an Innovation Methodology to Accelerate Clinical Trial Innovation within Your Organization

For more details on the Plenary Keynotes: www.scopesummit.com/keynotes
For more details on the Participant Engagement Award: www.scopesummit.com/participant-engagement-award

INTERACTIVE BREAKOUT DISCUSSION GROUPS

Concurrent breakout discussion groups are interactive, guided discussions hosted by a facilitator or set of co-facilitators to discuss some of the key issues presented earlier in the day’s sessions. Delegates will join a table of interest and become an active part of the discussion at hand. Bring your pharma, biotech, CRO, site, hospital or patient perspective to each of the discussions below. To get the most out of this interactive session and format please come prepared to share examples from your work, vet some ideas with your peers, be a part of group interrogation and problem solving, and, most importantly, participate in active idea sharing: www.scopesummit.com/breakouts